Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL. We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) (n=19) or lymphoid blast phase of chronic myelogenous leukemia (CML-LB) (n=15...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Benjamini, Ohad, Dumlao, Theresa Liu, Kantarjian, Hagop, O’Brien, Susan, Garcia-Manero, Guillermo, Faderl, Stefan, Jorgensen, Jeffrey, Luthra, Rajyalakshmi, Garris, Rebecca, Thomas, Deborah, Kebriaei, Partow, Champlin, Richard, Jabbour, Elias, Burger, Jan, Cortes, Jorge, Ravandi, Farhad
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196860/
https://ncbi.nlm.nih.gov/pubmed/24779033
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki